Ultragenyx Pharmaceutical Inc (RARE)
43.68
+1.31
(+3.09%)
USD |
NASDAQ |
Apr 22, 16:00
43.71
+0.03
(+0.07%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Revenue (TTM): 434.25M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 434.25M |
| September 30, 2023 | 410.20M |
| June 30, 2023 | 402.86M |
| March 31, 2023 | 383.89M |
| December 31, 2022 | 363.33M |
| September 30, 2022 | 343.37M |
| June 30, 2022 | 334.31M |
| March 31, 2022 | 331.95M |
| December 31, 2021 | 351.41M |
| September 30, 2021 | 359.56M |
| June 30, 2021 | 359.38M |
| March 31, 2021 | 334.12M |
| Date | Value |
|---|---|
| December 31, 2020 | 271.03M |
| September 30, 2020 | 215.08M |
| June 30, 2020 | 159.41M |
| March 31, 2020 | 121.85M |
| December 31, 2019 | 103.71M |
| September 30, 2019 | 84.38M |
| June 30, 2019 | 70.34M |
| March 31, 2019 | 58.99M |
| December 31, 2018 | 51.50M |
| September 30, 2018 | 37.65M |
| June 30, 2018 | 26.08M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
70.34M
Minimum
Jun 2019
434.25M
Maximum
Dec 2023
286.02M
Average
334.31M
Median
Jun 2022
Revenue (TTM) Benchmarks
| Corcept Therapeutics Inc | 482.38M |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 1.243B |
| FibroGen Inc | 147.75M |
| Rocket Pharmaceuticals Inc | -- |